impact factor
logo
 

Diagnosis

 

Assessment of sensitivity to change of the European Scleroderma Study Group activity index


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium. karin.melsens@ugent.be
  2. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University; and Department of Rheumatology, Ghent University Hospital, Belgium.
  3. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
  4. Department of Respiratory Medicine, Ghent University Hospital, Belgium.
  5. Department of Cardiology, Ghent University Hospital, Belgium.
  6. Department of Public Health, Biostatistics Unit, Ghent University, Belgium.
  7. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
  8. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University; Department of Rheumatology, Ghent University Hospital; and Begium Unit of Molecular Immunology and Inflammation, Inflammation Research Centre-VIB, Ghent, Belgium.
  9. Department of Rheumatology, Ghent University Hospital, Belgium.
  10. Department of Cardiology, Ghent University Hospital, Belgium.
  11. Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University; and Department of Rheumatology, Ghent University Hospital, Belgium.

CER9059
2016 Vol.34, N°5 ,Suppl.100
PI 0148, PF 0151
Diagnosis

Free to view
(click on article PDF icon to read the article)

PMID: 27463733 [PubMed]

Received: 19/10/2015
Accepted : 18/05/2016
In Press: 18/07/2016
Published: 13/10/2016

Abstract

OBJECTIVES:
The European Scleroderma Study Group (EScSG) activity index meets nearly all the OMERACT-standards of truth, discrimination and feasibility. The sensitivity to change remains to be attested. This study assesses sensitivity to change of the EScSG activity index in patients with early and severe diffuse cutaneous Systemic Sclerosis (dcSSc) treated with rituximab.
METHODS:
12-month follow-up (open-label study) of 14 consecutive patients with early dcSSc. Patients received an infusion of two times 1000 mg rituximab at month 0 and 6, together with 100 mg methylprednisolone. Clinical read outs (modified Rodnan skin score [mRSS], lung function and echocardiography) and EScSG activity index were performed at month 0, 3, 6 and 12. Mixed models analyses (MMA) were used to evaluate changes in parameters over time.
RESULTS:
There was a clinically significant change in skin score with a mean (SD) mRSS of 24.8 (4.44) at baseline and 10.4 (3.12) at month 12 (MMA p<0.001). Also the EScSG activity index decreased significantly, with a mean (SD) of 4.3 (1.79) at baseline and 0.7 (0.83) at month 12 (MMA p<0.001). The estimated mean change of the EScSG activity index was -3.6 (95%CI -4.9; -2.4) over 12 months. Indices of internal organ involvement remained stable throughout the study.
CONCLUSIONS:
A significant improvement of the EScSG activity index was observed, in line with the significant improvement of the mRSS and the stabilisation of internal organ involvement. To our knowledge, this is the first study to attest sensitivity to change of the EScSG activity index in the subset of ‘early’ dcSSc. Trial registration. ClinicalTrials.gov Registration, http://clinicaltrials.gov, number NCT00379431.

Rheumatology Article

Rheumatology Addendum